Article (Scientific journals)
Le medicament du mois. Rimonabant (Acomplia): premier antagoniste des recepteurs CB1 du systeme endocannabinoide.
Scheen, André; Van Gaal, L. F.
2008In Revue Médicale de Liège, 63 (1), p. 50-5
Peer reviewed
 

Files


Full Text
200801_11.pdf
Publisher postprint (654.18 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anti-Obesity Agents/pharmacology; Diabetes Mellitus, Type 2/prevention & control; Dyslipidemias/prevention & control; Humans; Piperidines/pharmacology; Pyrazoles/pharmacology; Receptors, Cannabinoid/antagonists & inhibitors
Abstract :
[en] Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. Clinical trials showed that, compared to placebo, rimonabant 20 mg/ day consistently increases weight loss, reduces waist circumference, improves atherogenic dyslipidaemia (low HDL cholesterol, high triglycerides, high small dense LDL), diminishes insulin resistance, reduces HbA1c levels, and contributes to lower blood pressure and C-reactive protein levels. Almost half of the most important metabolic effects occur beyond weight loss, suggesting direct peripheral effects of rimonabant, especially in visceral adipose tissue as suggested by the increase in adiponectin levels. Rimonabant at a daily dose of 20 mg is indicated as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factor(s) such as type 2 diabetes or dyslipidaemia. Adverse effects concern digestive tract (nausea, mostly transient) and psychological disorders (depressed mood, anxiety), in relation to the mechanism of action of the drug. Therefore, rimonabant is contra-indicated in case of depression and/or in patients receiving antidepressants.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Van Gaal, L. F.;  Hôpital Universitaire d’Anvers > Département de Diabétologie, Métabolisme et Nutrition clinique,
Language :
French
Title :
Le medicament du mois. Rimonabant (Acomplia): premier antagoniste des recepteurs CB1 du systeme endocannabinoide.
Alternative titles :
[en] Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system
Publication date :
2008
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
63
Issue :
1
Pages :
50-5
Peer reviewed :
Peer reviewed
Available on ORBi :
since 14 January 2009

Statistics


Number of views
406 (2 by ULiège)
Number of downloads
456 (3 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
2

Bibliography


Similar publications



Contact ORBi